by Lucy Hicks
Nearly 40% of adults with alopecia areata taking baricitinib, an oral Janus kinase (JAK) 1 and 2 inhibitor, see significant hair regrowth over 52 weeks, according to updated results from two phase 3 trials presented at the American Academy of Dermatology 2022 annual meeting in Boston, Massachusetts.
The results indicate improved response rates and hair growth among trial participants, said Brett King, MD, PhD, an associate professor of dermatology at the Yale University School of Medicine in New Haven, Connecticut. He is the lead author of the analyses and presented the research
